IDEXX Laboratories analyst consensus stays firm, shares trade below recent high
23.06.2026 - 13:36:48 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:33.
IDEXX Laboratories (US45168D1046) opens this Tuesday with a clear analyst consensus and a solid listing on the NASDAQ. Recent data from an independent forecast service shows the shares last traded around 545.73 US dollars on June 22, 2026, with analysts on that platform pointing to an average target of 709.14 US dollars.
What recent data shows
According to the PandaForecast coverage of IDEXX Laboratories, the latest session on June 22, 2026, closed negative, with a trading volume of 627,647 shares. The reported session data lists an open at 555.92 US dollars, a high at 562.74 US dollars, and a low at 540.99 US dollars, indicating a relatively contained intraday trading range for the NASDAQ-listed veterinary diagnostics specialist.
The same source cites a current value of 545.73 US dollars for IDEXX Laboratories shares on June 22, 2026, and an implied upside toward a 709.14 US dollar average target, based on aggregated analyst expectations. While PandaForecast itself is not a primary research house, the figures illustrate that market participants who follow such aggregations still see room above the latest quoted level, even after the most recent negative session.
Analyst sentiment and ratings
A February 2026 analyst-focused article on IDEXX Laboratories describes a "Moderate Buy" consensus rating, with 10 analysts in the sample, 7 assigning Buy and 3 Hold recommendations to the stock. That review notes IDEXX Laboratories shares around 562.09 US dollars at the time, and highlights that Wall Street analysts in that coverage expected the stock price to rise further over their horizon. Although the piece dates back to early 2026, it underscores that professional coverage of IDEXX Laboratories has leaned constructive, supported by recurring revenue in pet care diagnostics.
The same analysis stresses that IDEXX Laboratories had recently reported strong quarterly results and guidance for 2026, even though the shares traded lower on the day of that report. For retail investors, the combination of a "Moderate Buy" distribution, a double-digit number of active analyst opinions, and an above-market price target range gives a sense of how the S&P 500 healthcare name has been positioned in research lists, despite short-term volatility in NASDAQ trading.
All news and analysis on the IDEXX Laboratories shares
Further articles and data points on IDEXX Laboratories, including price history, analyst estimates and corporate disclosures, are collected in the dedicated topic section.
How IDEXX Laboratories makes its money
IDEXX Laboratories generates the bulk of its revenue from diagnostic and information technology products and services for veterinary practices, focusing on companion animal health. A May coverage of the company highlights an enhancement of the Fecal Dx antigen testing platform, designed to detect tapeworm species such as Taenia and Echinococcus in pets. Earlier in May, IDEXX Laboratories also announced that its SDMA renal biomarker would be integrated into Catalyst CLIPs, making comprehensive kidney assessments a standard element of widely used point-of-care chemistry profiles in veterinary clinics.
Where the IDEXX stock trades today
Based on the latest PandaForecast session data, IDEXX Laboratories shares (US45168D1046) trade on the NASDAQ at around 545.73 US dollars as of 2026-06-22, 16:00. This level sits below the cited recent high of 562.74 US dollars from the same session, and below the February 2026 reference around 562.09 US dollars, while still reflecting a substantial market valuation for the S&P 500 healthcare constituent.
IDEXX Laboratories at a glance
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- WKN: 888839
- Ticker: IDXX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 16:00): 545.73 US dollars
- Market cap: around 45 billion US dollars (as of 2026-06-22, based on recent NASDAQ data inference)
- Sector / industry: Health Care - Health Care Equipment & Supplies, Veterinary Diagnostics
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article provides a factual description of IDEXX Laboratories and its shares for informational purposes only and does not contain investment advice or recommendations. All data points are based on sources cited in the text and may change with new market information.
